NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
0.3380
Dollar change
+0.0054
Percentage change
1.62
%
Index- P/E- EPS (ttm)-1.08 Insider Own52.22% Shs Outstand41.61M Perf Week8.37%
Market Cap14.06M Forward P/E- EPS next Y-1.22 Insider Trans0.00% Shs Float19.88M Perf Month5.96%
Enterprise Value-40.31M PEG- EPS next Q-0.24 Inst Own29.12% Short Float1.66% Perf Quarter-47.20%
Income-48.19M P/S16.55 EPS this Y8.08% Inst Trans-3.49% Short Ratio1.67 Perf Half Y-60.56%
Sales0.85M P/B0.26 EPS next Y0.41% ROA-61.25% Short Interest0.33M Perf YTD-64.79%
Book/sh1.30 P/C0.26 EPS next 5Y- ROE-67.28% 52W High1.54 -78.05% Perf Year-75.86%
Cash/sh1.31 P/FCF- EPS past 3/5Y3.21% -19.41% ROIC-89.11% 52W Low0.22 53.57% Perf 3Y-95.41%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin85.38% Volatility11.49% 17.37% Perf 5Y-
Dividend TTM- EV/Sales-47.42 EPS Y/Y TTM42.38% Oper. Margin-5940.92% ATR (14)0.04 Perf 10Y-
Dividend Ex-Date- Quick Ratio14.68 Sales Y/Y TTM- Profit Margin-5682.19% RSI (14)49.44 Recom2.50
Dividend Gr. 3/5Y- - Current Ratio14.68 EPS Q/Q54.83% SMA20-1.45% Beta-1.18 Target Price4.00
Payout- Debt/Eq0.00 Sales Q/Q- SMA504.75% Rel Volume0.25 Prev Close0.33
Employees25 LT Debt/Eq0.00 EarningsMay 08 BMO SMA200-55.08% Avg Volume197.66K Price0.34
IPOJul 29, 2021 Option/ShortNo / Yes EPS/Sales Surpr.19.23% - Trades Volume49,146 Change1.62%
Date Action Analyst Rating Change Price Target Change
Apr-09-25Downgrade H.C. Wainwright Buy → Neutral
May-15-24Downgrade JP Morgan Overweight → Neutral
Feb-07-24Downgrade Jefferies Buy → Hold $7 → $1.50
Apr-17-23Initiated H.C. Wainwright Buy $18
Apr-10-23Initiated Wedbush Outperform $17
Dec-09-22Initiated JP Morgan Overweight $21
Feb-22-22Initiated JMP Securities Mkt Outperform $32
Aug-23-21Initiated Jefferies Buy $20
Aug-23-21Initiated Evercore ISI Outperform $40
Aug-23-21Initiated Cowen Outperform
Jun-12-25 08:00AM
May-08-25 08:00AM
Apr-29-25 08:00AM
Apr-09-25 10:58AM
07:21AM
08:00AM Loading…
Apr-08-25 08:00AM
05:27AM
Mar-13-25 08:00AM
Feb-25-25 08:00AM
Feb-12-25 05:29AM
Feb-11-25 08:00AM
Jan-10-25 08:00AM
Dec-10-24 08:00AM
Dec-06-24 06:48AM
Dec-02-24 08:00AM
08:00AM Loading…
Nov-27-24 08:00AM
Nov-26-24 08:00AM
Nov-25-24 08:00AM
Nov-22-24 07:01AM
Nov-21-24 08:00AM
Nov-07-24 08:00AM
Nov-05-24 02:59AM
Oct-29-24 08:00AM
Sep-30-24 08:00AM
Sep-23-24 08:00AM
Sep-10-24 08:00AM
Sep-09-24 05:15PM
Aug-29-24 08:00AM
Aug-27-24 08:00AM
Aug-14-24 12:00PM
08:00AM Loading…
Aug-08-24 08:00AM
Jul-09-24 08:00AM
Jun-17-24 08:00AM
May-31-24 07:00AM
May-10-24 06:30AM
May-09-24 01:54PM
10:14AM
08:00AM
May-07-24 08:00AM
Apr-17-24 04:01PM
Apr-12-24 10:23AM
Apr-11-24 07:43AM
Apr-10-24 04:01PM
01:01PM
Apr-01-24 10:05AM
Mar-12-24 08:00AM
Feb-26-24 08:00AM
Feb-06-24 09:46AM
08:00AM
Jan-04-24 08:00AM
Dec-20-23 08:00AM
Dec-09-23 12:00PM
Nov-28-23 07:00AM
Nov-09-23 08:00AM
Nov-08-23 08:00AM
Nov-02-23 09:15AM
Oct-03-23 08:00AM
Sep-03-23 12:00PM
Aug-31-23 08:00AM
Aug-08-23 08:00AM
Aug-02-23 08:00AM
Jul-11-23 08:00AM
Jun-29-23 07:00AM
Jun-24-23 03:30PM
Jun-09-23 09:15AM
Jun-01-23 08:00AM
May-29-23 09:55AM
May-12-23 09:55AM
May-09-23 08:00AM
May-08-23 08:00AM
Apr-06-23 08:00AM
Apr-03-23 08:00AM
Mar-15-23 09:15AM
Mar-10-23 09:35AM
Mar-06-23 02:49PM
08:00AM
07:30AM
Mar-02-23 09:01AM
Mar-01-23 08:00AM
Feb-27-23 07:00AM
Jan-31-23 04:05PM
Jan-05-23 08:00AM
Dec-15-22 08:00AM
Dec-14-22 06:39AM
Dec-12-22 05:55PM
Dec-01-22 07:00AM
Nov-29-22 08:00AM
Nov-17-22 05:39AM
Nov-11-22 08:00AM
Nov-10-22 11:51PM
09:15AM
Nov-07-22 08:00AM
07:30AM
Oct-06-22 08:38AM
Sep-28-22 12:37PM
08:00AM
Aug-31-22 08:00AM
Aug-08-22 08:00AM
Aug-02-22 08:00AM
Jul-06-22 07:37AM
Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.